Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (12349)	12/9/1997 10:25:00 PM
From: Miljenko Zuanic	Respond to of 32384

Hanry: Literature data are mixed on selectivity and overexpression of the specific PTPs subtype (alpha, beta, gamma, epsilon...) involved in dephosphorylation of the Tyrosine phosphorylated insulin receptor. I guess, based on Dr. Ullrich, that SUGN is working on alpha and epsilon subtype PTPs. From patents (in vitro study) they claim upregulating glucose cell uptake without insulin presence (Type I diabetes). Because I didn't found comparable clinical data for PTPs inhibitors in diabetes, I do not know value and medical application of this approach. Reason that I asked for your opinion. I am not correlating SUGN to LGND in diabetes/cancer. Because I am SUGN SH, my attention is to develop accurate value of this SUGN projects. >>I have always wondered about the relative merits of an approach that targetted the front end of the signalling pathway (Tyrosine phospoorylation and dephosphorylation), verses the back end (transcription factors and associated regulatory proteins). << Generally this is valid statement. In some cases, because of the so many different factors which characterize successful drug, front end may be in favor for signalling pathway induction/inhibition. Thanks again. mz